(Reuters) - Amicus Therapeutics Inc said its experimental drug was as effective as enzyme replacement therapies (ERTs) after 18 months in patients with an inherited disorder that leads to the abnormal build-up of fat. The company's shares soared 60 percent in premarket trading. Amicus said in April that the drug, migalastat HCl, significantly reduced the abnormal accumulation of fat, compared with a placebo, related to a rare genetic disorder that could lead to heart attack, stroke and kidney failure. The second late-stage trial was testing the drug against standard-of-care ERTs in 60 patients with a form of Fabry disease, Amicus said on Wednesday. via Health News Headlines - Yahoo News Read More Here..
No comments:
Post a Comment